Published in Genomics and Genetics Weekly, June 16th, 2006
Lexicon will receive $2 million in funding for the 1-year initial term of the grant.
SMA is characterized by a mutation in the SMN1 gene that leads to neurodegeneration. Under the grant, Lexicon will utilize its proprietary gene knockout technology to identify genes that, when knocked out,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics and Genetics Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.